Literature DB >> 29463916

Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity.

Geraldine J Ooi1,2, Arul Earnest3, William W Kemp4, Paul R Burton5,6, Cheryl Laurie5, Ammar Majeed4, Nathan Johnson7, Catriona McLean8, Stuart K Roberts4, Wendy A Brown5,6.   

Abstract

INTRODUCTION: In obese individuals, nonalcoholic fatty liver disease (NAFLD) is common but often goes undiagnosed, and therefore untreated. The presence of significant fibrosis is a key determinant of NAFLD progression, and liver steatosis has substantial cardiovascular implications. We aimed to determine the diagnostic accuracy of common noninvasive diagnostic tests for steatosis and fibrosis in the obese.
METHODS: We recruited 182 severely and morbidly obese individuals undergoing bariatric surgery (age 44 ± 12 years, body mass index 45.1 ± 8.3 kg/m2). Medical history, blood tests and liver biopsy were taken on the day of surgery. Serum steatosis and fibrosis scores were calculated. In a subgroup of patients, transient elastography with controlled attenuation parameter (TE/CAP) (n = 82) and proton magnetic resonance spectroscopy (1H-MRS) (n = 49) were performed.
RESULTS: 1H-MRS had excellent diagnostic accuracy for steatosis, with strong correlation to steatosis (r = 0.647, p < 0.001), good AUROC (0.852, p = 0.001), sensitivity (81.3%) and specificity (87.5%). However, due to low feasibility in this cohort (65.3% success), this was substantially decreased with intention-to-diagnose analysis (sensitivity 50.0%, specificity 60.9%). CAP had good feasibility (80.5%), and performed better in intention-to-diagnose analysis (AUROC 0.688, sensitivity 84.8%, specificity 47.2%). Serum steatosis scores performed poorly, with comparable accuracy to ALT. For significant fibrosis, TE had the best accuracy (AUROC 0.903, p = 0.007), which remained reasonable after intention-to-diagnose analysis (sensitivity 100%, specificity 59.0%). A combination approach using CAP with ALT for steatosis and TE with Forn index for fibrosis yielded reasonable overall accuracy.
CONCLUSIONS: 1H-MRS and TE/CAP had greatest accuracy for NAFLD-related steatosis and fibrosis. Failure rates in obesity significantly diminished diagnostic ability. Use of a combination of serum and imaging tests improved overall feasibility of assessment and diagnostic accuracy in obese individuals.

Entities:  

Mesh:

Year:  2018        PMID: 29463916     DOI: 10.1038/s41366-018-0007-3

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  11 in total

1.  Reply to "Crashing NASH in Patients Listed for Bariatric Surgery".

Authors:  Geraldine J Ooi; Paul R Burton; William W Kemp; Stuart K Roberts; Wendy A Brown
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

2.  Measurement of Liver Stiffness with 2D-Shear Wave Elastography (2D-SWE) in Bariatric Surgery Candidates Reveals Acceptable Diagnostic Yield Compared to Liver Biopsy.

Authors:  Tannaz Jamialahmadi; Mohsen Nematy; Ali Jangjoo; Ladan Goshayeshi; Reza Rezvani; Kamran Ghaffarzadegan; Mehdi Jabbari Nooghabi; Payman Shalchian; Mahtab Zangui; Zeinab Javid; Saeid Doaei; Farnood Rajabzadeh
Journal:  Obes Surg       Date:  2019-08       Impact factor: 4.129

3.  Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity.

Authors:  Magdalena Eilenberg; Petra Munda; Judith Stift; Felix B Langer; Gerhard Prager; Michael Trauner; Katharina Staufer
Journal:  Hepatobiliary Surg Nutr       Date:  2021-10       Impact factor: 7.293

4.  Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults.

Authors:  Richard K Sterling; Wendy C King; Mandana Khalili; David E Kleiner; Amanda S Hinerman; Mark Sulkowski; Raymond T Chung; Mamta K Jain; M Auricio Lisker-Melman; David K Wong; Marc G Ghany
Journal:  Dig Dis Sci       Date:  2021-02-08       Impact factor: 3.487

5.  Noninvasive Evaluation of Liver Function in Morbidly Obese Patients.

Authors:  Patrick H Alizai; Isabella Lurje; Andreas Kroh; Sophia Schmitz; Tom Luedde; Julia Andruszkow; Ulf P Neumann; Florian Ulmer
Journal:  Gastroenterol Res Pract       Date:  2019-02-03       Impact factor: 2.260

6.  Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis.

Authors:  Changzhou Cai; Xin Song; Xueyang Chen; Weihua Zhou; Qi Jin; Shenghui Chen; Feng Ji
Journal:  Can J Gastroenterol Hepatol       Date:  2021-01-20

7.  Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.

Authors:  Philippe Garteiser; Laurent Castera; Muriel Coupaye; Sabrina Doblas; Daniela Calabrese; Marco Dioguardi Burgio; Séverine Ledoux; Pierre Bedossa; Marina Esposito-Farèse; Simon Msika; Bernard E Van Beers; Pauline Jouët
Journal:  JHEP Rep       Date:  2021-09-30

8.  Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease.

Authors:  Dieter Furthner; Christian-Heinz Anderwald; Peter Bergsten; Anders Forslund; Joel Kullberg; Håkan Ahlström; Hannes Manell; Iris Ciba; Harald Mangge; Katharina Maruszczak; Pia Koren; Sebastian Schütz; Susanne Maria Brunner; Anna Maria Schneider; Daniel Weghuber; Katharina Mörwald
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-02       Impact factor: 5.555

9.  Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.

Authors:  Ayşegül Avcu; Eda Kaya; Yusuf Yilmaz
Journal:  Turk J Gastroenterol       Date:  2021-05       Impact factor: 1.852

10.  Higher cut-off values of non-invasive methods might be needed to detect moderate-to-severe steatosis in morbid obese patients: a pilot study.

Authors:  Daniella Braz Parente; Hugo Perazzo; Fernando Fernandes Paiva; Carlos Frederico Ferreira Campos; Carlos José Saboya; Silvia Elaine Pereira; Felipe d'Almeida E Silva; Rosana Souza Rodrigues; Renata de Mello Perez
Journal:  Sci Rep       Date:  2020-09-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.